The impact of bodyweight and body condition on behavioral testing for painful diabetic neuropathy in the streptozotocin rat model

Neuroscience Letters

Volumn 436, Issue 1, 2008, Pages 13-18

  Hoybergs, Yves M J J ^a   Biermans, Ria L V ^a   Meert, Theo F ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Body condition score; Diabetes; Ethics; Mechanical hyperalgesia; Neuropathy; Tactile allodynia

Indexed keywords

STREPTOZOCIN;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BODY CONSTITUTION; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; HYPERALGESIA; MALE; NERVE CONDUCTION; NOCICEPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMAL EXPERIMENTATION; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; MALE; PAIN; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY;

EID: 41749090878     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.02.051     Document Type: Article

References (29)

1. Ahlgren S.C., and Levine J.D. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience 52 (1993) 1049-1055
2. Ahlgren S.C., and Levine J.D. Mechanical hyperalgesia in streptozotocin-diabetic rats is not sympathetically maintained. Brain Res. 616 (1993) 171-175
3. Brown M.J., Sumner A.J., Greene A.G., Diamond S.M., and Asbury A.K. Distal neuropathy in experimental diabetes mellitus. Ann. Neurol. 8 (1980) 168-178
4. Calcutt N.A., Jorge M.C., Yaksh T.L., and Chaplan S.R. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 68 (1996) 293-299
5. Chen D., and Wang M.W. Development and application of rodent models for type 2 diabetes. Diab. Obes. Metab. 4 (2005) 307-317
6. Chu P.C., Lin M.T., Shian L.R., and Leu S.Y. Alterations in physiologic functions and in brain monoamine content in streptozotocin-diabetic rats. Diabetes 35 (1986) 481-485
7. Cohen M.P., and Klein C.V. Glomerulopathy in rats with streptozotocin diabetes. Accumulation of glomerular basement membrane analogous to human diabetic nephropathy. J. Exp. Med. 149 (1979) 623-631
8. Courteix C., Eschalier A., and Lavarenne J. Streptozotocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53 (1993) 81-88
9. Fox A., Eastwood C., Gentry C., Manning D., and Urban L. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 81 (1999) 307-316
10. Garofano A., Czernichow P., and Breant B. Beta-cell mass and proliferation following late fetal and early postnatal malnutrition in the rat. Diabetologia 41 (1998) 1114-1120
11. Hirose K., Osterby R., Nozawa M., and Gundersen H.J. Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int. 21 (1982) 889-895
12. Junod A., Lambert A.E., Stauffacher W., and Renold A.E. Diabetiogenic action of Streptozotocin: Relationship of dose to metabolic response. J. Clin. Invest. 48 (1969) 2129-2139
13. Li F., Abatan O.I., Kim H., Burnett D., Larkin D., Obrosova I.G., and Stevens M.J. Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol. Dis. 22 (2006) 669-676
14. Lynch J.J., Jarvis M.F., and Kowaluk E.A. An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain. Eur. J. Pharmacol. 364 (1999) 141-146
15. Malcangio M., and Tomlinson D.R. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin-diabetic rats. Pain 76 (1998) 151-157
16. Mohseni S., and Hildebrand C. Neuropathy in diabetic BB/Wor rats treated with insulin implants. Acta Neuropathol. 96 (1998) 144-150
17. Moss H.E., Lincoln J., and Burnstock G. A study of bladder dysfunction during streptozotocin-induced diabetes in the rat using an in vitro whole bladder preparation. J. Urol. 138 (1987) 1279-1284
18. Palm F., Ortsater H., Hansell P., Liss P., and Carlsson P.-O. Differentiating between effects of streptozotocin per se and subsequent hyperglycemia on renal function and metabolism in the streptozotocin-diabetic rat model. Diab. Metab. Res. Rev. 20 (2004) 452-459
19. Patel J., and Tomlinson D.R. Nerve conduction impairment in experimental diabetes-proximodistal gradient of severity. Muscle Nerve 22 (1999) 1403-1411
20. Randall L.O., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. 61 (1957) 409-419
21. Rittenhouse P.A., Marchand J.E., Chen J., Kream R.M., and Leeman S.E. Streptozotocin-induced diabetes is associated with altered expression of peptide-encoding mRNAs in rat sensory neurons. Peptides 17 (1996) 1017-1022
22. Romanovsky D., Hastings S.L., Stimers J.R., and Dobretsov M. Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. J. Peripher. Nerv. Syst. 9 (2004) 62-69
23. Russell J.W., Sullivan K.A., Windebank A.J., Herrmann D.N., and Feldman E.L. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol. Dis. 6 (1999) 347-363
24. Schutta M.H. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J. Cardiometab. Syndr. 2 (2007) 124-130
25. Sima A.A.F., and Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 42 (1999) 773-788
26. Srinivasan K., and Ramarao P. Animal models in type 2 diabetes research: An overview. Indian J. Med. Res. 125 (2007) 451-472
27. Tapp R.J., Zimmet P.Z., Harper C.A., McCarty D.J., Chitson P., Tonkin A.M., Soderberg S., Taylor H.R., Alberti K.G.M.M., Tuomilehto J., and Shaw J.E. Six year incidence and progression of diabetic retinopathy: Results from the Mauritius diabetes complication study. Diab. Res. Clin. Practice 73 (2006) 298-303
28. Wei M., Ong L., Smith M.T., Ross F.B., Schmid K., Hoey A.J., Burstow D., and Brown L. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circulation 12 (2003) 44-50
29. Witte R.S., Ryan L.M., Schutt A.J., Carbone P.P., and Engstrom P.F. PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Invest New Drugs 16 (1998) 315-318